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Abstract Anal ﬁssure is one of the most common and
painful proctologic diseases. Its treatment has long been
discussed and several different therapeutic options have
been proposed. In the last decades, the understanding of its
pathophysiology has led to a progressive reduction of
invasive and potentially invalidating treatments in favor of
conservative treatment based on anal sphincter muscle
relaxation. Despite some systematic reviews and an
American position statement, there is ongoing debate about
the best treatment for anal ﬁssure. This review is aimed at
identifying the best treatment option drawing on evidence-
based medicine and on the expert advice of 6 colorectal
surgeons with extensive experience in this ﬁeld in order to
produce an Italian position statement for anal ﬁssures.
While there is little chance of a cure with conservative
behavioral therapy, medical treatment with calcium chan-
nel blockers, diltiazem and nifepidine or glyceryl trinitrate,
had a considerable success rate ranging from 50 to 90%.
Use of 0.4% glyceryl trinitrate in standardized fashion
seems to have the best results despite a higher percentage
of headache, while the use of botulinum toxin had incon-
sistent results. Nonresponding patients should undergo
lateral internal sphincterotomy. The risk of incontinence
after this procedure seems to have been overemphasized in
the past. Only a carefully selected group of patients,
without anal hypertonia, could beneﬁt from anoplasty.
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Introduction
Anal ﬁssure is one of the most frequent and painful anal
diseases and its clinical management is still controversial
despite several systematic reviews. Therefore, the aim of
this paper was to establish a position paper on ﬁssure
management based on the currently available literature and
discussion among a group of Italian experts on this topic.
Deﬁnitions, epidemiology, and etiology
The commonly accepted deﬁnition of anal ﬁssure is: ‘‘A
linear ulcer of the anoderm, distal to the dentate line,
generally located in the posterior midline’’ [1–4].
Anal ﬁssure is very painful, because it affects the mul-
tilayer squamous epithelium of the anoderm, which is richly
innervated with pain ﬁbers. During defecation, the lesion is
stretched with consequent painful symptomatology, which
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DOI 10.1007/s10151-011-0683-7can persist for a certain amount of time [5] and be accom-
panied by slight bleeding. The pain can be so intense as to
induce the patient to avoid defecation with consequent
hardening of the feces and exacerbation of the problem [1,
6].
Anal ﬁssures are considered to be acute if they have
been present for less than 6 weeks, superﬁcial, and have
well-demarcated edges. They are considered chronic,
instead, if they have been present for more than 6 weeks
and have keratinous edges, if there is a sentinel node and
hypertrophied anal papillae and if the ﬁbers of the internal
anal sphincter are visible [1, 6–8].
Primary anal ﬁssures are not caused by underlying
chronic disease whereas secondary anal ﬁssures are asso-
ciated with other diseases, such as chronic inﬂammatory
intestinal diseases, human immunodeﬁciency virus tuber-
culosis, syphilis, and some neoplasms.
Primary anal ﬁssures are most frequent in young adults
of both sexes [9].
In 80–90% of the cases, they are located in the posterior
midline [4, 5, 9], and more rarely in the anterior region.
Associated pathologies should be suspected if there are
anal ﬁssures in other regions than the posterior region [1, 4,
10]. Anterior lesions are more frequent in women than in
men [5, 11].
Anal ﬁssures are not common in patients older than
65 years, and in this age group must be suspected to be
associated with other pathologies [6]. Data are not avail-
able on its prevalence in the general population. The life-
time incidence is calculated to be 11% [12].
In Italy anal ﬁssures represent the second most common
cause of a proctology specialist visit after hemorrhoidal
pathology. In England, in the period 2005–2006, the inci-
dence of hospitalization for anal ﬁssure was calculated to
be 1.56 per 10,000 inhabitants [13]. According to the data
of the 2009 Annual Report prepared by the SICCR (Italian
Society of Colorectal Surgery), in 2009, a total of 5,199
patients were observed for anal ﬁssure at Italian colo-
proctology centers, 1924 (37%) of whom underwent sur-
gery [14].
Etiology
There has been much debate about the causes of primary
anal ﬁssures. Historically, the eliciting factor was consid-
ered to be the trauma resulting from the passage of hard
feces [15], but less than 25% of the cases of chronic anal
ﬁssures are associated with constipation [1, 9, 12]. Fur-
thermore, many anal ﬁssures of traumatic origin heal
whereas others do not. For many years an association with
internal anal sphincter (IAS) hypertonia has been evident
[16, 17], although in elderly patients [18, 19] and in post-
partum patients [20] cases of anal ﬁssure have been
reported that are associated with a normal or hypotonic
IAS.
The basal tone of the IAS is affected by various sub-
stances, including nitric oxide (NO) [21]. In patients with
anal ﬁssures, the synthesis of NO in the IAS is reduced in
comparison with the controls [22]. Manometry studies have
demonstrated an increased IAS tone and a reduction in
anodermal vascular blood ﬂow, mainly in the posterior
region [23, 24] and showed that in patients who beneﬁted
from sphincterotomy surgery or from anal stretch sphincter
hypertonia was reduced and blood ﬂow increased. This
pathogenetic mechanism can explain the achievement of a
high rate of healing with medical therapies able to improve
blood ﬂow [25] and/or to reduce hypertonia [6].
Diagnosis
The diagnosis is based on the presence of intense pain, with
possiblebleeding,duringorafterdefecationandisconﬁrmed
by a careful inspection of the posterior commissure of the
anus. The following are the pain characteristics of anal ﬁs-
sure: intense burning pain that appears immediately or later
after evacuation of the bowels, of variable duration, descri-
bed as passing a ‘‘razor blade’’ or ‘‘broken glass’’ [1–4].
The majority of anal ﬁssures are visible upon simple
divarication of the glutei and during straining [9], at the
level of the posterior commissure (80–90%) or the anterior
commissure (10%) or more rarely the anteroposterior
commissure and in these cases digital exploration can be
avoided [26]. In some cases, the lesion can be identiﬁed
only through the use of an anoscope.
Spasm and pain can make diagnosis impossible [1].
Therefore, exploration under anesthesia is sometimes
indispensable.
Upon inspection primary chronic anal ﬁssure presents as
wide and deep, with sphincter ﬁbers visible, frequent pres-
ence of a sentinel pseudopolyp, hypertrophied anal papillae,
and keratinous edges [2, 6–8]. If the diagnosis of primary
analﬁssureisindoubt,forexampleinthecaseofanalﬁssure
in a region other than the posterior region, or in the presence
of multiple anal ﬁssures or a painless anal ﬁssure that does
not resolved with the therapy, examination under anesthesia
with biopsy and appropriate cultures is indispensable [6].
The differential diagnosis includes hemorrhoids [6] and
other neoplastic, infective, or chronic inﬂammatory
pathologies in the anal region.
Conservative treatment
Improving diet and defecation habits is a good long-term
strategy for reducing gastrointestinal problems.
Therefore, patients with primary chronic anal ﬁssures
are advised to assume liquids and ﬁber supplements as well
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baths. The amount of ﬁber should be increased gradually to
avoid problems of ﬂatulence.
These simple measures are able to reduce the pain and
should be recommended to all patients. If bulk-forming
laxatives are not sufﬁcient, osmotic laxatives can be tried.
To reduce the pain, local anesthetics can be used as addi-
tional measures but only for short periods of time due to the
risk of skin sensitization [2, 10, 27].
It is important to emphasize that, in the case of acute anal
ﬁssures, conservative treatment can provide a cure in 87% of
the cases, while in chronic forms this ﬁgure is 50% [28–30].
Medical therapy
The goal of medical treatment for chronic anal ﬁssure is to
achieve a temporary reduction of pressure of the anal canal,
to facilitate the healing of the ﬁssure (‘‘reversible sphinc-
terotomy’’), thereby reducing muscle tone. Various mech-
anisms can be used: increasing NO, direct depletion of
intracellular calcium, stimulation of muscarinic receptors,
inhibition of alpha-adrenergic receptors, or stimulation of
beta-adrenergic receptors [1].
In all of the most recent guidelines topical nitrates and
topical calcium channel blockers are included among the
pharmacological therapy options [1–3, 6]. From a search of
PubMed using the most common keywords associated with
this pathology (chronic anal ﬁssures, topical nitrates, top-
ical nifedipine, topical diltiazem), we found 68 trials using
glyceryl trinitrate (GTN), 20 trials using diltiazem, and just
5 trials with nifepidine.
Topical nitrates
Since the discovery of the role of NO as an inhibitor of IAS
tone [21], the use of nitrates has been shown to reduce anal
hypertonia [31] and in many clinical contexts it has become
the ﬁrst-line therapy for chronic anal ﬁssures [7].
The introduction of topical nitrates has had an important
impact on the reduction of the number of surgical proce-
dures, especially in several European countries [32].
The ﬁrst trials that were conducted demonstrated a cure
rate of 59–86% [33–36], but without standardization of the
doses. A study focusing on the optimal nitroglycerin oint-
ment dose and dosing interval was carried out by Bailey
and colleagues [36].
Glyceryl trinitrate has been tested mainly in two for-
mulations: 0.2 and 0.4%.
0.2% GTN
Randomized controlled trials conducted with 0.2% GTN
ointment had cure rates of between 50 and 68% [37, 38].
A recent Cochrane review of the medical therapy for
anal ﬁssures demonstrates that as regards the cure rate
topical nitrates are marginally but signiﬁcantly superior to
placebo [39]. It is important to note the signiﬁcant effect
these drugs had on reducing pain [35–37], and the positive
effect on the patient’s well-being, physical activity, and
vitality, the fundamental components of quality of life [40].
The percentage of recurrence in some patients after
therapy ended was correlated with regaining hypertonia
[41]. A review by Nelson [42] reports a recurrence rate of
approximately 50%.
The most common adverse event correlated with topical
nitrates therapy is transitory headache reported in an
average of 25% of the patients and easily manageable with
a therapy based on mild pain relievers [42]. Although
frequent, the development of headache does not lead to
reduced compliance. In fact, as some clinical experiences
demonstrate, for the patient the pain associated with anal
ﬁssure is decidedly more serious than that caused by the
headache, and therefore interruption of therapy due to this
adverse event is rare [39, 43].
In any case, the headache can easily be managed by
informing the patient that it may occur and that it can be
kept under control by means of a suitable pharmacological
therapy or with some simple techniques, such as, for
example, beginning the therapy with lower doses than the
therapeutic doses, to reach the recommended dosage regi-
men within 4–5 days.
0.4% GTN
Recently an ointment containing 0.4% GTN has been
industrially manufactured.
A recent trial conducted in Italy on patients affected by
chronic anal ﬁssures treated with an industrially manufac-
tured ointment containing 0.4% GTN demonstrated a
clinical cure in 54% of the patients. Pain symptoms,
measured by means of the visual analog scale (VAS),
disappeared in 62% of the patients. Furthermore, a corre-
lation was demonstrated between pain reduction and
improvement in all of the components of quality of life
(activity, anxiety/depression) [44].
An analysis presented by Sands in 2005 [45] compared
the results of treatment with 0.4% GTN versus placebo and
0.2% GTN versus placebo. A signiﬁcant reduction in anal
pain caused by GTN in comparison with placebo was
demonstrated only in the ﬁrst group of patients.
Treatment with 0.4% GTN achieved this result in a
shorter amount of time (6 days vs. 18 days) than treatment
with 0.2% GTN.
In the same trial, the tolerability proﬁle was similar in
the two groups and comparable to the groups reported in
the literature, with episodes of transitory headache that did
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123not prevent 90% of the patients with this symptom from
completing therapy.
Calcium channel blockers
The calcium channel blockers reduce muscle tone. Cur-
rently, only two industrial preparations based on the
channel blockers nifedipine and diltiazem exist on the
market in a topical form. Only the former is available in
Italy, while the latter is available in the UK and in the
United States.
Diltiazem
Two percent diltiazem was used in several clinical expe-
riences, obtaining a cure in 75% of the patients. The doses
used varied greatly among the trials [10], almost all of
which were conducted without comparison of diltiazem to
placebo, with a length of therapy sometimes greater than
8 weeks [46], and with limited patient case histories [47].
The use of diltiazem has been associated with the
development of migraine and pruritus ani [48].
Recurrence is also a problem for this class of drug. In
one of the few long-term trials [49], more than 60% of the
patients experienced recurrence within 2 years after the
end of therapy.
Nifedipine
Regarding nifedipine, there have been very few trials
conducted with the drug at different concentrations in the
Mediterranean area (Italy, Turkey, Greece, and Israel).
In Italy, an industrially manufactured ointment with a
formulation of 0.3% nifedipine ?1.5% lidocaine is avail-
able. With this preparation was published a single double-
blind, randomized, prospective trial on 110 patients with
chronic anal ﬁssures (55 treated with nifedipine ? 1.5%
lidocaine and 55 treated with 1% hydrocortisone ? 1.5%
lidocaine). The reported cure rate after 6 weeks of treat-
ment was 95% compared to 16% of the control group,
without any systemic adverse reaction in the group treated
with nifedipine ? lidocaine [50]. This trial, the results of
which are not in line with the international literature on
medical therapy for anal ﬁssures and have not yet been
conﬁrmed by other authors, presents important limits,
including the use of cortisone, which could have blocked
the healing process of ﬁssures in the control group [51].
Duration of therapy
In the literature, therapy is administered for at least
6–8 weeks. A reduction in pain generally occurs within
2 weeks from the beginning of therapy.
Recent work by Gagliardi and colleagues [44] con-
ducted with 0.4% GTN demonstrated that pain during
evacuation, measured by means of the VAS scale,
improves signiﬁcantly after 2, 4, and 6 weeks of treatment,
while the extension of therapy up to 12 weeks does not
yield any further beneﬁts.
Furthermore, this trial demonstrated a signiﬁcant
improvement in quality of life, which was already appre-
ciable after 14 days, with continuous improvement up until
the end of treatment.
In the Phase III clinical trials conducted by Sands, pain
relief was achieved more quickly with the 0.4% ointment
than with the 0.2% ointment (6 days vs. 18 days).
Also, in the only trial reported with nifedipine ? lido-
caine, the duration of the treatment for chronic anal ﬁssures
was 6 weeks [50].
The Clinical Knowledge Summaries [3] indicate topical
nitrates as the ﬁrst line of pharmacological treatment
together with conservative therapy, and they recommend
the continuation of treatment for at least 6–8 weeks, sug-
gesting, in cases of persistent anal ﬁssures, further cycles of
medical therapy before considering surgery.
Comparison of pharmacological therapies
The Cochrane review [42], which considered only those
trials conducted with galenic formulations of 0.2% GTN
versus calcium channel blockers, concludes that it is not
possible to demonstrate any signiﬁcant differences with
regard to the cure rate, in part because of the scarcity of
comparative trials. However, in a double-blind, random-
ized, prospective trial [52] that compared 0.2% GTN and
topical calcium channel blockers, the percentages of
recurrence were found to be signiﬁcantly higher in the
group treated with calcium channel blockers (42% vs.
31%), while the results regarding reduction of pain were
found to be virtually identical. Instead, no direct compar-
isons exist between ointment containing 0.4% GTN and
topical calcium channel blockers.
Botulinum toxin
The proposal to use botulinum toxin, based on its possible
reduction of internal anal sphincter tone, faces some dif-
ﬁculties in daily clinical practice in connection with
locating the drug, the nonstandardized dose [53], the
injection site that is not well-deﬁned [54, 55], the inva-
siveness of the method, and the higher cost of treatment
[56].
A high percentage of recurrence (40–55% at 3–4 years)
[57] and a signiﬁcant incidence of adverse events such as
fecal incontinence (10%) [58, 59], hematomas, and sub-
cutaneous infections [55] are described after treatment with
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long-term efﬁcacy.
A randomized trial of topical nitrates versus botulinum
toxin showed greater efﬁcacy of the nitrates at 2 weeks
(cure rate of 52% vs. 24%, P\0.05) [60].
Other drugs
Other drugs have been proposed for medical treatment of
anal ﬁssures: muscarinic agonists, adrenergic agonists and
antagonists, and phosphodiesterase inhibitors.
However, their role still remains to be determined. Local
anesthetics such as lidocaine can act as analgesics, like
paracetamol and nonsteroidal anti-inﬂammatory drugs.
[23].
Surgical options
Surgery should be reserved for those cases in which non-
surgical treatments fail. From the most recent trials it
appears to be important that medical therapy be extended
to at least 6 weeks before it is considered to have failed.
The patient must be informed of the risk of fecal inconti-
nence, which should always be discussed when obtaining
the informed consent of the patient [2, 7].
Anal stretch, reintroduced into anal ﬁssure therapy in
1964 [61] with signiﬁcant success rates [62], is, however,
associated with recurrence rates varying from 2% to 80%
[63, 64], a high risk of incontinence (up to 51%) [65, 66],
and is widely criticized despite a reported cure rate of
approximately 90% [63].
More recently, an attempt was made to standardize anal
dilatation with pressurized balloons (controlled pneumatic
dilatation) to reduce the incidence of sphincter injury [67,
68] with appreciable results. In Italian clinical practice,
anal dilators are frequently used, although there is very
little scientiﬁc evidence regarding the beneﬁts of this
treatment [69].
Lateral internal sphincterotomy (LIS), performed with an
openorclosedtechnique, involvesanincisionoftheinternal
sphincter, more or less extended, distal to the dentate line,
with the possible excision of the sentinel node and the
hypertrophied papillae [68, 70]. The cure rate after LIS is
higherthan90%[71].Bothtechniquesdemonstratevirtually
identical efﬁcacy [72–74] and a similar incidence of incon-
tinence,eventhoughinonetrial[75]theincidenceofsoiling
after open LIS was signiﬁcantly higher than after closed LIS
[P\0.001]. Complications include bleeding, hematoma,
abscess, and ﬁstulas. Lateral internal sphincterotomy
achieves efﬁcacy rates higher than those of nonsurgical
therapy, but is associated with an increased risk of minor
fecal incontinence after surgery (approx. 10%). Therefore,
extreme prudence is recommended in considering LIS for
high risk patients, such as the elderly, multiparous women,
patients with previous biliopancreatic bypass for obesity,
and patients with previous proctologic surgery.
Lateral internal sphincterotomy is superior to ﬁssurec-
tomy and posterior sphincterotomy because it is associated
with faster healing, less pain, and less postoperative
incontinence [68].
The technique of anoplasty, with or without sphincter-
otomy, is only considered an alternative to LIS, but there
are no randomized comparison trials [76]. It can be indi-
cated in the following situations: sphincter hypotonia or
normal tone, previous anal surgery, and diagnostic doubt.
Diathermy coagulation and cryosurgery of anal ﬁssure
are nonrecommended procedures.
Therapeutic algorithm
In the various therapeutic algorithms proposed [1, 7, 23,
77], nonsurgical, conservative, medical therapy is consid-
ered ﬁrst-line treatment.
In consideration of the note of AIFA, the Italian drug
regulatory agency, published in February 2009 in an issue
of Reazioni, their ofﬁcial bulletin, which advises against
the use of lidocaine-based anesthetics (lidocaine is con-
tained in the formulation of the nifedipine-based ointment)
on skin lesions, the panel is of the opinion that the ﬁrst-line
pharmacological therapy for primary chronic anal ﬁssure
can be based on the 0.4% GTN ointment, also based on the
more extensive international literature that is currently
available on GTN.
Should medical therapy fail, open or closed lateral
internal sphincterotomy is the surgical option of choice.
The use of botulinum toxin and dilatations is not currently
considered a suitable treatment. Anoplasty can be per-
formed in the speciﬁc cases cited above.
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